Roberta Duncan

Get more Bioprocess insight with our FREE newsletter sign me up Newsletter | December 20, 2022 Rewind to the end of December 2019 for a minute. The annual “top columns” edition of our newsletter that year featured a few popular pieces on the regulatory activity of the day. There were a couple of articles on cleaning and validation. We saw a dash of aseptic filling content here, a pinch of GMP advice there. It was pretty standard stuff.

By Giles Campion, EVP, head of R&D and CMO, Silence Therapeutics Small interfering RNAs (siRNAs) are short sequences of RNA that interfere with gene expression, reducing or eliminating the expression of a disease-related protein by targeting its corresponding mRNA. siRNAs could treat a wide array of diseases. How does it differ from other therapeutic modalities such as gene therapy and gene editing?

Newsletter | February 11, 2022 By Roberta Duncan, VP, mRNA Program Lead, Seqirus While the first paper to show that mRNA could be used as a vaccine was published in 1990, its efficacy in a Phase 3 clinical trial was not determined until 2020. Now, as we look to the future of vaccine development, mRNA has become a priority in many vaccine research programs. Among other benefits, the tech can be moved into clinical trials more rapidly than other platforms.